ClinicalTrials.gg
RecruitingNCT05614050Updated Nov 9, 2026

The Prognosis of Patients After PCI:a Multi-center Study in China

An observational study in Inflammation, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Observational

How we know

From the registry’s dates

  • Started Nov 2022; still recruiting 4 years later.
Updated Nov 9, 2026Sponsor changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,400
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 113 studies in Inflammation with a site in China — 38 open to participants now, 39 under way, 1 of them phase 3. Inflammation · China.

Planned enrollment
5th of 39
2,400 · median 266
Started
2022
with 6 others
Observational
39 of 113
14 open now
Primary completion
2027-11
later than 30 of 38 live
Registered
66th of 113
by date

Among the 113 studies in Inflammation with a site in China, this one is the 5th largest by planned enrollment of the 39 observational ones that give a count, is one of 7 that started in 2022, is one of 39 observational ones, reaches primary completion later than 30 of the 38 other live ones, and was the 66th registered.

Inflammation

3,545 studies on the registry are indexed under Inflammation; 650 are open to participants now.

Browse Inflammation studies →

Open to participants now

38 of the 113 studies in Inflammation with a site in China are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies in Inflammation with a site in China, or all of them as a file.
02

Study summary

Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.

03

Conditions studied

  • Inflammation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

The hospitalized patients with coronary heart disease completing all planned PCI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who understand and sign the voluntarily;
  • Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
  • The hospitalized patients with coronary heart disease undergoing PCI;
  • Complete all planned PCI during hospitalization.

Exclusion criteria

Exclusion Criteria:

  • Acute, chronic or recurrent infectious diseases;
  • Immune diseases or immune-related diseases;
  • Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs;
  • Pregnant women, lactating women or women of childbearing age who do not use effective measures;
  • The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. MACCE

    A composite of all-cause death, nonfatal myocardial infarction, nonfatal stroke, ischemia-driven revascularization

    Time frame: 12 months

Secondary outcomes

  1. all-cause death

    Occurrence of all-cause death

    Time frame: 12 months

  2. cardiovascular death

    Occurrence of cardiovascular death

    Time frame: 12 months

  3. nonfatal myocardial infarction

    Occurrence of nonfatal myocardial infarction

    Time frame: 12 months

  4. nonfatal stroke

    Occurrence of of nonfatal stroke

    Time frame: 12 months

  5. ischemia-driven revascularization

    Occurrence of ischemia-driven revascularization

    Time frame: 12 months

  6. hospitalization for unstable angina

    Occurrence of hospitalization for unstable angina

    Time frame: 12 months

  7. stent/scaffold thrombosis

    Occurrence of stent/scaffold thrombosis

    Time frame: 12 months

  8. in-stent restenosis

    Occurrence of in-stent restenosis

    Time frame: 12 months

  9. bleeding

    Occurrence of bleeding

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Xiang Cheng, Doctor · Contactnathancx@hust.edu.cn · +8602785726011
    • Xiang Cheng, Doctor · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2027, 60 months after the start.

Of 355 non-industry observational studies under Inflammation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 85. This study's planned 60 months is above that.

Counting every sponsor, half of 371 studies reached it within 40 months; a quarter within 18 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2022
First posted
Nov 14, 2022
StartActual
Nov 1, 2022
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sponsor
Collaborators added: The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture; collaborators removed: Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Sponsor Collaborators added: The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture; collaborators removed: Central Hospital of Enshi Tujia and Miao Autonomous Prefecture
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05614050
Collaborators
Shandong Provincial Hospital, The First Affiliated Hospital of Zhengzhou University, The First Affiliated Hospital of Xiamen University, Shanxi Cardiovascular Hospital, First People's Hospital of Xianyang, Yichang Central People's Hospital, Jingzhou Central Hospital, The First Hospital of Wuhan, Wuhan Central Hospital, Wuhan Fourth Hospital, Fifth Hospital in Wuhan, Chinese Academy of Medical Sciences, Fuwai Hospital, Wuhan Asia Heart Hospital, The First Affiliated Hospital of Anhui Medical University, The Central Hospital of Enshi Tujia And Miao Autonomous Prefecture, Hubei University of Medicine
Responsible party
Xiang Cheng (Director of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Principal investigator
First posted
Nov 14, 2022
Start date
Nov 1, 2022
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Miao Yu
Contact
yumiaodavid@126.com
+862785726009
Xiang Cheng, Doctor
principal investigator · Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion